In breast cancer, lower levels of adiponectin are associated with an increased risk of the disease, and it can inhibit cancer cell proliferation by suppressing oncogenic pathways such as PI3K/AKT and mTOR [9,10]. Here, ADIPOQ is linked to cancer.